Booy, R.Richmond, P.Nolan, T.McVernon, J.Marshall, H.Nissen, M.Reynolds, G.Ziegler, J.Heron, L.Lambert, S.Caubet, M.Mesaros, N.Boutriau, D.2011-12-062011-12-062011The Pediatric Infectious Disease Journal, 2011; 30(4):340-3420891-36681532-0987http://hdl.handle.net/2440/68527Hib-primed but MenC-naive toddlers (N = 433) were randomized to receive 1 dose of Hib-MenC-TT or separate Hib-TT and MenC-CRM197 vaccines. One month later, noninferiority was demonstrated for serum bactericidal anti-MenC antibodies (rSBA) and Hib antipolyribosylribitol phosphate (PRP) antibodies; >99% in both groups had rSBA titer ≥ 8 or anti-PRP concentration ≥ 0.15 μg/mL. After 12 months, rSBA titer ≥ 8 persisted in 86.7% and 76.4%, and anti-PRP concentration ≥ 0.15 μg/mL persisted in 98.8% and 100% of children, respectively.en© 2011 Lippincott Williams & Wilkins, Inc.Haemophilus influenzae type bNeisseria meningitidis serogroup Cantibody persistencetoddlersImmediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of ageJournal article002010438110.1097/INF.0b013e31820013d20002884387000172-s2.0-7995469091431610Marshall, H. [0000-0003-2521-5166]